{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:29:04Z","timestamp":1787581744296,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI1553300"],"award-info":[{"award-number":["U01AI1553300"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cerebral malaria (CM) is a common cause of febrile coma among African children. Despite treatment with highly efficacious intravenous artesunate, CM remains associated with high mortality and neurologic sequelae. In a mouse CM model, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) demonstrated robust efficacy as a potential adjuvant therapy. Before testing DON in children with CM, we investigated tolerability in African adults, including individuals with malaria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an open-label, prospective, dose-escalation, phase 1 clinical trial of single-dose intravenous DON in Blantyre, Malawi. Participants included healthy adults and adults with uncomplicated malaria, enrolled in dose-cohorts of 10 and administered DON at 0.1, 1.0, 5.0, or 10 mg\/kg. We assessed adverse events (AEs) and plasma pharmacokinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty healthy adults and 38 adults with uncomplicated malaria received DON. Transient, asymptomatic creatinine elevation occurred 12 hours postinfusion in 18% of all participants. Nausea and vomiting were uncommon at 0.1 and 1.0 mg\/kg but occurred more frequently at 5.0 and 10 mg\/kg DON. All DON-related AEs resolved rapidly, without sequelae, and did not significantly differ between healthy and uncomplicated malaria participants. In healthy adults, maximum plasma concentrations increased proportional to dose, but adults with malaria had greater than dose-proportional increases. Terminal half-life ranged from 1.7 to 4.1 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DON was well tolerated in healthy adults and adults with uncomplicated malaria. Higher doses were associated with transient gastrointestinal AEs. Pharmacokinetics were minimally influenced by malaria disease. These results provide critical data to guide dosing strategies for adjunctive DON in children with CM.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT05478720.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag121","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:41:43Z","timestamp":1771936903000},"page":"e1226-e1237","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-\n                    <scp>L-<\/scp>\n                    Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-8971","authenticated-orcid":false,"given":"Brittany A","family":"Riggle","sequence":"first","affiliation":[{"name":"Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3001-2386","authenticated-orcid":false,"given":"Athanasios","family":"Chamzas","sequence":"additional","affiliation":[{"name":"Center for Translational Medicine, University of Maryland School of Pharmacy , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-9870","authenticated-orcid":false,"given":"Mathangi","family":"Gopalakrishnan","sequence":"additional","affiliation":[{"name":"Center for Translational Medicine, University of Maryland School of Pharmacy , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-0946","authenticated-orcid":false,"given":"Osward M","family":"Nyirenda","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-1375","authenticated-orcid":false,"given":"Nginache","family":"Nampota-Nkomba","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]},{"name":"Department of Internal Medicine, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E","family":"Mallewa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoda","family":"Masonga","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Manyozo","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingsley","family":"Zuze","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice M","family":"Liomba","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Alt","sequence":"additional","affiliation":[{"name":"Johns Hopkins Drug Discovery, Johs Hopkins University School of Medicine, Baltimore, Maryland ,","place":["USA"]},{"name":"Department of Neurology, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4059-2453","authenticated-orcid":false,"given":"Rana","family":"Rais","sequence":"additional","affiliation":[{"name":"Johns Hopkins Drug Discovery, Johs Hopkins University School of Medicine, Baltimore, Maryland ,","place":["USA"]},{"name":"Department of Neurology, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-4157","authenticated-orcid":false,"given":"Barbara","family":"Slusher","sequence":"additional","affiliation":[{"name":"Johns Hopkins Drug Discovery, Johs Hopkins University School of Medicine, Baltimore, Maryland ,","place":["USA"]},{"name":"Department of Neurology, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4266-607X","authenticated-orcid":false,"given":"Neshen","family":"Moodley","sequence":"additional","affiliation":[{"name":"Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis H","family":"Miller","sequence":"additional","affiliation":[{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K","family":"Pierce","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-8671","authenticated-orcid":false,"given":"Nicole F","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]},{"name":"Department of Pediatrics, Division of Critical Care Medicine, Nationwide Children's Hospital , Columbus, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-581X","authenticated-orcid":false,"given":"Matthew B","family":"Laurens","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-0691","authenticated-orcid":false,"given":"Douglas G","family":"Postels","sequence":"additional","affiliation":[{"name":"Blantyre Malaria Project, Kamuzu University of Health Sciences , Blantyre ,","place":["Malawi"]},{"name":"Division of Neurology, The George Washington University, Children's National Hospital , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026082409270752900_jiag121-B1","doi-asserted-by":"crossref","first-page":"101073","DOI":"10.1016\/j.lanmic.2025.101073","article-title":"WHO world malaria report 2024","volume":"6","author":"Venkatesan","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026082409270752900_jiag121-B2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1400116","article-title":"Brain swelling and death in children with cerebral malaria","volume":"372","author":"Seydel","year":"2015","journal-title":"New Engl J Med"},{"key":"2026082409270752900_jiag121-B3","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3174\/ajnr.A3035","article-title":"Acute brain MRI findings in 120 Malawian children with cerebral malaria: new insights into an ancient disease","volume":"33","author":"Potchen","year":"2012","journal-title":"Am J Neuroradiol"},{"key":"2026082409270752900_jiag121-B4","doi-asserted-by":"crossref","first-page":"e00193","DOI":"10.1128\/mSphere.00193-17","article-title":"Magnetic resonance imaging of cerebral malaria patients reveals distinct pathogenetic processes in different parts of the brain","volume":"2","author":"Mohanty","year":"2017","journal-title":"Msphere"},{"key":"2026082409270752900_jiag121-B5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/INF.0000000000002573","article-title":"Amount of brain edema correlates with neurologic recovery in pediatric cerebral malaria","volume":"39","author":"Kampondeni","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2026082409270752900_jiag121-B6","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1516544112","article-title":"Targeting glutamine metabolism rescues mice from late-stage cerebral malaria","volume":"112","author":"Gordon","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026082409270752900_jiag121-B7","doi-asserted-by":"crossref","first-page":"E12024","DOI":"10.1073\/pnas.1812909115","article-title":"MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice","volume":"115","author":"Riggle","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026082409270752900_jiag121-B8","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1172\/JCI133474","article-title":"CD8+ T cells target cerebrovasculature in children with cerebral malaria","volume":"130","author":"Riggle","year":"2020","journal-title":"J Clin Invest"},{"key":"2026082409270752900_jiag121-B9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/1097-0142(195711\/12)10:6<1138::AID-CNCR2820100608>3.0.CO;2-K","article-title":"Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease","volume":"10","author":"Magill","year":"1957","journal-title":"Cancer"},{"key":"2026082409270752900_jiag121-B10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jnci\/22.2.433","article-title":"A clinical study of the comparative effect of nitrogen mustard and DON in patients with bronchogenic carcinoma, Hodgkin's disease, lymphosarcoma, and melanoma","volume":"22","author":"Krantz","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"2026082409270752900_jiag121-B11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1172\/JCI104057","article-title":"Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine","volume":"39","author":"Grayzel","year":"1960","journal-title":"J Clin Invest"},{"key":"2026082409270752900_jiag121-B12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0025-7125(16)33879-2","article-title":"Management of choriocarcinoma and related tumors of uterus and testis","volume":"45","author":"Li","year":"1961","journal-title":"Med Clin North Am"},{"key":"2026082409270752900_jiag121-B13","first-page":"83","article-title":"A comparison of the effectiveness of standard dose 6-mercaptopurine, combination 6-mercaptopurine and DON, and high-loading 6-mercaptopurine therapies in treatment of the acute leukemias of childhood - results of a cooperative study","volume":"18","author":"Sullivan","year":"1962","journal-title":"Cancer Chemoth Rep"},{"key":"2026082409270752900_jiag121-B14","first-page":"1247","article-title":"Phase-I study of 6-diazo-5-oxo-L-norleucine (DON)","volume":"64","author":"Sklaroff","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"2026082409270752900_jiag121-B15","first-page":"1031","article-title":"Phase-I and pharmacokinetic studies of DON","volume":"65","author":"Kovach","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"2026082409270752900_jiag121-B16","first-page":"1215","article-title":"Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses","volume":"66","author":"Earhart","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"2026082409270752900_jiag121-B17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00216936","article-title":"Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas","volume":"8","author":"Earhart","year":"1990","journal-title":"Invest New Drugs"},{"key":"2026082409270752900_jiag121-B18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00170760","article-title":"Phase-I study and clinical-pharmacology of 6-diazo-5-oxo-L-norleucine (DON)","volume":"3","author":"Rahman","year":"1985","journal-title":"Invest New Drugs"},{"key":"2026082409270752900_jiag121-B19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00262746","article-title":"Pharmacokinetic and phase-I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children","volume":"21","author":"Sullivan","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026082409270752900_jiag121-B20","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1200\/jco.2011.29.15_suppl.3049","article-title":"A phase I schedule optimization study of pegylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients (pts) with advanced solid tumors","volume":"29","author":"Unger","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026082409270752900_jiag121-B21","first-page":"1665","article-title":"Phase II study on DON in patients with previously treated advanced lung cancer","volume":"66","author":"Eagan","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"2026082409270752900_jiag121-B22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000421-198210000-00014","article-title":"Phase-II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal-carcinoma","volume":"5","author":"Lynch","year":"1982","journal-title":"Am J Clin Oncol-Canc"},{"key":"2026082409270752900_jiag121-B23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000421-198306000-00012","article-title":"A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma","volume":"6","author":"Rubin","year":"1983","journal-title":"Am J Clin Oncol"},{"issue":"Suppl","key":"2026082409270752900_jiag121-B24","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/jco.2008.26.15_suppl.2533","article-title":"A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors","volume":"26","author":"Mueller","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026082409270752900_jiag121-B25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13063-023-07808-w","article-title":"DON in pediatric cerebral malaria, a phase I\/IIA dose-escalation safety study: study protocol for a clinical trial","volume":"25","author":"Nampota-Nkomba","year":"2024","journal-title":"Trials"},{"key":"2026082409270752900_jiag121-B26","author":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available from:"},{"key":"2026082409270752900_jiag121-B27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1440-1746.2005.03884.x","article-title":"Jaundice in malaria","volume":"20","author":"Anand","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"2026082409270752900_jiag121-B28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pt.2023.01.005","article-title":"The kidney-brain pathogenic axis in severe falciparum malaria","volume":"39","author":"Conroy","year":"2023","journal-title":"Trends Parasitol"},{"key":"2026082409270752900_jiag121-B29","doi-asserted-by":"crossref","first-page":"651739","DOI":"10.3389\/fimmu.2021.651739","article-title":"Immunopathology of acute kidney injury in severe malaria","volume":"12","author":"Katsoulis","year":"2021","journal-title":"Front Immunol"},{"key":"2026082409270752900_jiag121-B30","doi-asserted-by":"crossref","first-page":"1177242","DOI":"10.3389\/fnhum.2023.1177242","article-title":"Cerebrospinal fluid biomarkers provide evidence for kidney-brain axis involvement in cerebral malaria pathogenesis","volume":"17","author":"Conroy","year":"2023","journal-title":"Front Hum Neurosci"},{"key":"2026082409270752900_jiag121-B31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1535-7163.MCT-17-1148","article-title":"We're not \u201cDON\u201d yet: optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine","volume":"17","author":"Lemberg","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026082409270752900_jiag121-B32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0169-4758(86)90126-2","article-title":"L-Glutamine influx in malaria-infected erythrocytes\u2014target for antimalarials","volume":"2","author":"Elford","year":"1986","journal-title":"Parasitol Today"},{"key":"2026082409270752900_jiag121-B33","doi-asserted-by":"crossref","first-page":"e1008930","DOI":"10.1371\/journal.ppat.1008930","article-title":"Insights into malaria pathogenesis gained from host metabolomics","volume":"16","author":"Colvin","year":"2020","journal-title":"Plos Pathogens"},{"key":"2026082409270752900_jiag121-B34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2026082409270752900_jiag121-B35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/1348-0421.12724","article-title":"Tuberculosis patients display a high proportion of CD8+ T cells with a high cytotoxic potential","volume":"63","author":"Chavez-Galan","year":"2019","journal-title":"Microbiol Immunol"},{"key":"2026082409270752900_jiag121-B36","doi-asserted-by":"crossref","first-page":"e0127422","DOI":"10.1128\/mbio.01274-22","article-title":"Glutamine is required for M1-like polarization of macrophages in response to Mycobacterium tuberculosis infection","volume":"13","author":"Jiang","year":"2022","journal-title":"mBio"},{"key":"2026082409270752900_jiag121-B37","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1038\/s41467-023-43304-0","article-title":"Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis","volume":"14","author":"Parveen","year":"2023","journal-title":"Nat Commun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag121\/67139365\/jiag121.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/5\/e1226\/67139365\/jiag121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/5\/e1226\/67139365\/jiag121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:27:16Z","timestamp":1787578036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/5\/e1226\/8499844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag121","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2026,2,26]]}}}